These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24271274)

  • 1. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
    Ghamande S; Lin CC; Cho DC; Shapiro GI; Kwak EL; Silverman MH; Tseng Y; Kuo MW; Mach WB; Hsu SC; Coleman T; Yang JC; Cheng AL; Ghalib MH; Chuadhary I; Goel S
    Invest New Drugs; 2014 Jun; 32(3):445-51. PubMed ID: 24271274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
    Royce ME; Hoff PM; Dumas P; Lassere Y; Lee JJ; Coyle J; Ducharme MP; De Jager R; Pazdur R
    J Clin Oncol; 2001 Mar; 19(5):1493-500. PubMed ID: 11230496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.
    Arnold SM; Rinehart JJ; Tsakalozou E; Eckardt JR; Fields SZ; Shelton BJ; DeSimone PA; Kee BK; Moscow JA; Leggas M
    Clin Cancer Res; 2010 Jan; 16(2):673-80. PubMed ID: 20068096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
    Langevin AM; Casto DT; Thomas PJ; Weitman SD; Kretschmar C; Grier H; Pratt C; Dubowy R; Bernstein M; Blaney S; Vietti T
    J Clin Oncol; 1998 Jul; 16(7):2494-9. PubMed ID: 9667269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.
    Iwasa S; Yamamoto N; Shitara K; Tamura K; Matsubara N; Tajimi M; Lin AB; Asou H; Cai Z; Inoue K; Shibasaki Y; Saito K; Takai H; Doi T
    Cancer Sci; 2018 Oct; 109(10):3216-3223. PubMed ID: 30040168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
    Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
    Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
    J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
    Gelmon K; Hirte H; Fisher B; Walsh W; Ptaszynski M; Hamilton M; Onetto N; Eisenhauer E
    Invest New Drugs; 2004 Aug; 22(3):263-75. PubMed ID: 15122073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
    Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
    Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
    J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
    Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.